Most Recent Articles by Carina Storrs, PhD
Evidence suggests that starting on systemic drug therapy immediately may be the best approach for some patients with metastatic RCC.
Three specific subtypes of multiple myeloma were found to drive higher incidence rates among individuals of African descent.
Genomic and proteomic studies of medulloblastoma samples helped researchers characterize new cancer subtypes and targets.
Immunotherapy may supplant sunitinib in RCC, except for in patients who cannot tolerate checkpoint inhibition.
The combinatorial approach is not, furthermore, limited to chemotherapy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Fermented Dairy and Cancer
- Evidence Grows Linking BIA-ALCL to Textured Surface of Some Breast Implants
- Immunotherapy Plus Chemotherapy May Turn Cold Tumors Hot
- Increased Risk of Myeloma in African Americans Driven By Higher Rates of 3 Disease Subtypes
- SURTIME Trial: Surgery May Not Be Most Appropriate Frontline Treatment in mRCC
- Risk of Rare Blood Cancers Rises After Solid Tumor Chemotherapy
- Leading Cause of Death in Follicular Lymphoma Remains Disease Itself
- Long-Term Outcomes of Axicabtagene Ciloleucel: ZUMA-1
- Biosimilar Cancer Treatment Ontruzant Gets FDA Approval
- In Mice, Lithium Shown to Reverse Dysfunction Related to Brain Tumor Compression